CEO Bruce Downey exercised options for and sold 405,000 shares of the firm's stock, Barr announces Feb. 20. The options were granted in 1994 and 1995 and would have expired between August 2004 and Sept. 2005. Downey used a portion of the proceeds to purchase and hold 27,000 incentive-based options, bringing his holdings of the firm's common shares to 286,000. The CEO has been granted about 1.8 mil. options since 1993, Barr says. The firm is awaiting a decision from the FDA on the Rx-to-OTC switch of its emergency contraceptive Plan B (see story p. 4)...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.
Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.
